Biltricide
What is this? Biltricide is a medicine with praziquantel. It treats infections caused by flukes (tiny worms).
What's happening? There is less Biltricide available now. Other similar medicines can be used instead.
Does this affect me? If you take Biltricide, your supply may be limited. Ask your doctor or pharmacist for help.
What should I do? Do not stop taking your medicine without advice. Talk to your pharmacist or doctor about other options.
🤖 Denne letforståelige oversigt er automatisk genereret ud fra den officielle meddelelse fra myndigheden ved hjælp af AI. Den er udelukkende til generel information — ikke medicinsk rådgivning. Vedrørende beslutninger om din sundhed, skal du altid konsultere en farmaceut eller læge og læse den officielle kilde, der er linket nedenfor.
📋 Fra den officielle meddelelse fra myndigheden
Opdateret for 1 uge siden- Først udgivet
- 26/08/2025
- Berørte lægemidler
- Biltricide
- Berørte styrker
- 600 mg film-coated tablets
- Lagerstatus
- Ongoing
- Terapirigt område (MESH)
- Trematode Infections
- Start på forsyningsmangel
- 26/08/2025
- Tilgængelighed af alternativer
- Yes
- Internationalt ikke-ejendomsretligt navn (INN) eller fællesnavn
- praziquantel
Sideindhold
Mangel på lager
There is a shortage of Biltricide in the European Union/European Economic Area (EU/EEA).
Biltricide contains the active substance praziquantel and is used for the treatment of infections caused by trematodes (parasitic worms).
The company informed EMA that it is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine. This has led to a shortage of Biltricide in the EU.
The shortage is not related to a quality defect of the product or a safety issue.
The shortage affects all Member States where the product is marketed: Germany, France and the Netherlands. Other countries that import Biltricide are also affected.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party supports the MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- The company that markets Biltricide is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU. This has led to a shortage of the medicine in the EU.
- For patients with a trematode infection other than schistosomiasis, healthcare professionals should consider alternative treatment options.
- For patients with schistosomiasis, there is no other effective treatment available in the EU. Healthcare professionals should consult local or national guidelines on how to manage these patients.
- For additional information consult your country’s shortage register or contact your national competent authority.
- The company that markets Biltricide, a medicine used to treat certain parasitic (worm) infections, is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU.
- Other treatments are available for most parasitic infections; your doctor will discuss with you the best alternative treatment option.
- There is no treatment alternative for schistosomiasis in the EU; your doctor will manage your condition in line with relevant guidelines.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Årsag til mangel
The company informed EMA that it is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine. This has led to a shortage of Biltricide in the EU.
The shortage is not related to a quality defect of the product or a safety issue.
Berørte medlemsstater
The shortage affects all Member States where the product is marketed: Germany, France and the Netherlands. Other countries that import Biltricide are also affected.
Overvågning af mangel
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party supports the MSSG and monitors and reports events that could affect the supply of medicines in the EU.
Anbefalinger til sundhedspersonale
- The company that markets Biltricide is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU. This has led to a shortage of the medicine in the EU.
- For patients with a trematode infection other than schistosomiasis, healthcare professionals should consider alternative treatment options.
- For patients with schistosomiasis, there is no other effective treatment available in the EU. Healthcare professionals should consult local or national guidelines on how to manage these patients.
- For additional information consult your country’s shortage register or contact your national competent authority.
Anbefalinger til patienter og pårørende
- The company that markets Biltricide, a medicine used to treat certain parasitic (worm) infections, is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU.
- Other treatments are available for most parasitic infections; your doctor will discuss with you the best alternative treatment option.
- There is no treatment alternative for schistosomiasis in the EU; your doctor will manage your condition in line with relevant guidelines.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Nøgleoplysninger
- Medicines affected
- Biltricide
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- praziquantel
- Therapeutic area (MESH)
- Trematode Infections
- Strengths affected
- 600 mg film-coated tablets
- Availability of alternatives
- Yes
Nøgledatoer
- Start of supply shortage
- First published
Relateret medicinsk information
🔬 Medicinske/tekniske detaljer Til fagfolk
INN: praziquantel · Strengths: 600 mg film-coated tablets · Area: Trematode Infections · Alternatives: Yes
Alle oplysninger på denne side stammer fra den officielle meddelelse fra myndighederne. Vi oversætter og opsummerer den; vi tilføjer eller redigerer ikke fakta.
